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Abstract
Insights into factors underlying causes of familial Alzheimer’s disease (AD), such as mutant forms of L-amyloid precursor
protein and presenilins, and those conferring increased risk of sporadic AD, such as isoforms of apolipoprotein E and
polymorphisms of K2-macroglobulin, have been rapidly emerging. However, mechanisms through which amyloid L-peptide
(AL), the fibrillogenic peptide most closely associated with neurotoxicity in AD, exerts its effects on cellular targets have only
been more generally outlined. Late in the course of AD, when AL fibrils are abundant, non-specific interactions of amyloid
with cellular elements are likely to induce broad cytotoxicity. However, early in AD, when concentrations of AL are much
lower and extracellular deposits are infrequent, mechanisms underlying cellular dysfunction have not been clearly defined.
The key issue in elucidating the means through which AL perturbs cellular properties early in AD is the possibility that
protective therapy at such times may prevent cytotoxicity at a point when damage is still reversible. This brief review focusses
on two cellular cofactors for AL-induced cellular perturbation: the cell surface immunoglobulin superfamily molecule RAGE
(receptor for advanced glycation endproducts) and ABAD (AL binding alcohol dehydrogenase). Although final proof for the
involvement of these cofactors in cellular dysfunction in AD must await the results of further in vivo experiments, their
increased expression in AD brain, as well as other evidence described below, suggests the possibility of specific pathways for
AL-induced cellular perturbation which could provide future therapeutic targets. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The traditional view that pathologic e¡ects of
amyloid result from passive accumulation of ¢brillo-
genic material displacing cellular elements is being
revised in view of observations indicating that L-
sheet ¢brils actively modulate cellular behavior be-
fore substantial amyloid accumulation occurs. Mice
overexpressing transgenes for mutant forms of L-
amyloid precursor protein (LAPP), those resulting
in increased production of amyloid L-peptide (AL),
display electrophysiologic and behavioral changes
prior to evidence of amyloid deposition [1,2]. Clini-
copathologic features of Alzheimer’s disease (AD)
demonstrate that synaptic loss, rather than amyloid
plaque burden, correlates most closely with altered
cognitive function [3,4]. These observations do not
necessarily discount a role for AL in AD, but, rather,
indicate that large plaque-like accumulations of amy-
loid are unlikely to be key pathogenic features early
in the disease process. This view is consistent with a
role for recently identi¢ed dimers and di¡usible non-
¢brillar forms of AL to which cytotoxic e¡ects have
been attributed [5,6].
The ‘amyloid hypothesis’ has received considerable
support from several lines of evidence [7^11]. First,
LAPP variants resulting in overproduction of AL(1^
42), the more amyloidogenic form, relative to AL(1^
40), have a causative role in familial AD [12^14].
Second, mutant presenilins, the most common ab-
normality found in familial AD, are also associated
with altered processing of LAPP resulting in greater
amounts of AL(1^42) [12,15^18]. Third, the risk of
developing sporadic AD appears increased in the
presence of certain apoE isoforms, and apoE has
been linked to amyloidogenesis in transgenic animals
[12,19^21]. Finally, polymorphisms of K2-macroglo-
bulin have also been linked to sporadic AD, and this
protease inhibitor may contribute to a degradative
pathway for AL [22,23]. Although these data suggest
a role for AL in the pathogenesis of AD, the mech-
anisms through which AL exerts its toxic e¡ects re-
main to be de¢ned. The view that insights into path-
ophysiologically relevant mechanisms for induction
of cell stress in AD can be gained from experiments
in which micromolar (5^50 WM) levels of AL(25^35)
are added to any type of cultured cell has been chal-
lenged. On the one hand, it is true that ¢brillar ma-
terial can have toxic e¡ects on a range of cells [24^
28]. The intrinsic toxicity of high levels of ¢brils
themselves could result from generation of oxygen
free radicals by AL ¢brils (in the absence of any
cellular elements) [29], or their destabilization of
membranes resulting in changed intracellular calcium
homeostasis and eventual cell death [24,30]. Such ex-
periments may address pathologic mechanisms oper-
ative late in the course of AD. However, these ex-
perimental conditions are less likely to provide
insights pertaining to early mechanisms of cellular
perturbation in AD or other amyloidoses, when the
concentration of amyloid is low, though cellular dys-
function is already manifest.
Our work has addressed the possibility that cellu-
lar cofactors might have a central role in mediating
the pathogenic e¡ects of amyloid on vulnerable tar-
get cells early in AD, as well as in other amyloidoses.
These cofactors could serve to magnify the biologic
response to amyloid by triggering signal transduction
mechanisms amplifying cell stress, as well as trigger-
ing mechanisms buttressing a protective response.
This brief paper will review evidence that receptor
for advanced glycation endproducts (RAGE) and
AL binding alcohol dehydrogenase (ABAD) com-
prise potentially important cell surface and intracel-
lular targets of AL, respectively.
2. Role of receptor for advanced glycation
endproducts (RAGE) in AL-induced cell stress
RAGE is a multiligand member of the immuno-
globulin superfamily of cell surface molecules [31^
33]. Its extracellular portion is comprised of one V-
type followed by two C-type domains, and bears
greatest homology to other members of this family
such as the neural cell adhesion molecule (NCAM)
and muc-18. The N-terminal V-domain appears to
have a central role in the engagement of RAGE li-
gands. The receptor has a single transmembrane
spanning domain and a short, highly charged cyto-
solic tail which has a key role in mediating intracel-
lular signalling as shown by the dominant-negative
e¡ect consequent to its deletion [33]. RAGE was ini-
tially identi¢ed during our studies to identify cellular
interaction sites for advanced glycation endproducts
(AGEs) [31,32], non-enzymatically glycoxidized ad-
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ducts which accumulate in states of hyperglycemia
and oxidant stress [34^37]. As AGE modi¢cation oc-
curs most readily on intracellular lysine-rich polypep-
tides whose turnover is delayed, it is not surprising
that paired helical ¢lament tau displays AGE epi-
topes [38^41]. This observation led us to explore the
possibility that AGE modi¢cation of AL might ren-
der it a ligand for RAGE. At this point, two lines of
inquiry in our laboratory converged; radioligand
binding studies with glycated/non-glycated AL, and
experiments to identify a cell surface receptor for AL.
First, we studied glycation of AL, in view of evidence
that glycoxidized forms of the amyloid peptide were
apparently present in vivo [42]. We observed that
glycation of AL under in vitro conditions produced
a species which easily precipitated in aqueous solu-
tion, precluding further studies with cultured cells.
However, when we tested the control, non-glycated
AL, we were surprised to observe dose-dependent
binding to RAGE. Meanwhile, another line of inves-
tigation in our laboratory had just achieved the pu-
ri¢cation of a polypeptide derived from lung based
on its capacity to bind AL. The N-terminal sequence
of this polypeptide proved identical to RAGE. These
observations led us to explore the role of RAGE as a
cell surface receptor for AL [43].
AL assembles into varied and complex multimeric
structures [44^46]. Thus, it is not surprising that sev-
eral classes of molecules might participate in its rec-
ognition by cellular surfaces. Interaction of AL with
heparan sulfate proteoglycans [47,48], for example,
may provide a reservoir of cell surface amyloid which
then interacts with other sites, such as RAGE, the
macrophage scavenger receptor (MSR) [49,50] or the
p75 neurotrophin receptor [51]. The MSR, expressed
by microglia, is most likely to participate in cellular
uptake and degradation of AL, providing an impor-
tant clearance mechanism [49,50,52]. This would be
analogous to the role of MSR in other pathophysio-
logic settings [53,54]. Alternatively, the serpin en-
zyme complex (SEC) receptor and the K5L1 interact
with monomeric AL [55^57]. These ¢ndings imply
their possible participation in physiologic functions
of the low amounts of AL produced throughout life,
or in the regulation of extracellular levels of AL,
preventing substantial increases presaging ¢brillogen-
esis. More additions to the list of cell-associated
binding sites for AL can be anticipated, as its inter-
action with multiple target molecules, such as the
tumor necrosis factor receptor [58], is tested. The
challenge posed by these observations is to determine
the relevance of a particular receptor/binding site to
the cellular e¡ects of AL, and, most importantly, to
the biology of AD.
RAGE is an excellent candidate as a cofactor pro-
moting AL-induced cell stress based on several lines
of evidence. First, the pattern of RAGE expression
does not suggest a critical role for the receptor in
mature animals under physiologic conditions, but,
rather, supports a role in propagating sustained cel-
lular stress in pathophysiologic states, such as AD.
Although RAGE is present at high levels early in
development (virtually all cortical neurons express
RAGE in the neonatal period according to studies
in rodents) [59], expression of the receptor falls o¡
during maturity, with only an occasional cortical
neuron staining positively [43,60]. However, closely
paralleling the development of pathologic conditions,
Fig. 1. Expression of RAGE antigen and transcripts in AD brain. (A,B) Immunostaining with anti-RAGE IgG in AD brain (A) and
age-matched control brain (B). A shows double staining in which RAGE is shown in red and AL in black (the latter displayed with
anti-AL IgG). (C,D) In situ hybridization using riboprobes for RAGE in AD brain (C) and age-matched control brain (D). Adapted
from [43].
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RAGE expression is enhanced [43,60^64]. Thus, in
AD brain, RAGE is evident in neurons, microglia,
and astrocytes (Fig. 1), especially those proximal to
deposits of AL and in neurons bearing neuro¢brillary
tangles. The presence of cells displaying high levels of
RAGE near accumulations of RAGE ligands ap-
pears to be a salient feature of RAGE biology. In
the context of diabetes, for example, where tissues
are rich in AGE-ligands of RAGE, cells expressing
the receptor are closely apposed to the glycated ad-
ducts [64,65]. A possible basis for these observations
has been provided by analysis of the RAGE pro-
moter which has shown the presence of two func-
tional NF-kB DNA binding sites capable of regulat-
ing receptor expression [66]. Both AGEs and AL
cause RAGE-dependent nuclear translocation of
NF-kB [43,67,68]. The RAGE gene itself is therefore
likely one of the targets of RAGE-mediated NFkB
activation. Thus, RAGE binding to AL initiates an
ascending spiral of cellular perturbation, causing in-
creased expression of the receptor, and sustained
RAGE-induced cellular perturbation. This is quite
di¡erent than other ligand^receptor systems, such
as the LDL receptor, in which ligand down-regulates
receptor expression [69].
In contrast to the expression of the MSR which is
limited to mononuclear phagocytes, RAGE is
present not only on cells of monocyte lineage, but
also on a range of other cell types whose function
is perturbed by AL. Starting with monocyte-like cells,
AL binding to RAGE on microglia causes cellular
activation with resultant expression of cytokines,
such as tumor necrosis factor (TNF)-K [21]. Com-
pared with the outcome of AL binding MSR [50],
RAGE does not e¡ectively internalize and degrade
AL [52]. On neurons, two examples of the consequen-
ces of AL binding to RAGE include suppression of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
(MTT) reduction [70] and activation of NF-kB re-
sulting in enhanced expression of macrophage-colony
stimulating factor (M-CSF) [43,67]. COS cells trans-
fected to overexpress RAGE displayed enhanced sen-
sitivity to suppression of MTT reduction in the pres-
ence of increasing concentrations of AL, compared
with mock-transfected controls (Fig. 2A). Further-
more, a line of PC12 cells which expressed RAGE
endogenously showed diminished MTT reduction in
the presence of AL. The latter was restored in a dose-
dependent manner by adding extracellular, soluble
portion of the receptor, termed sRAGE, which inter-
cepts the interaction of AL with cell surface RAGE
(Fig. 2B,C). Consistent with these data, RAGE-bear-
ing cells showed enhanced NF-kB activation and
toxic morphological changes in the presence of AL,
including retraction of cellular processes. In each of
these experiments, it was evident that RAGE-medi-
ated potentiation of AL-induced cell stress occurred
at the lower range of AL concentrations (1039-1036
M), whereas at higher levels of amyloid peptide
(v 1035 M), RAGE independent modulation of cel-
lular function occurred (Fig. 2A,B). These data were
consistent with the concept that RAGE-dependent
Fig. 2. Expression of RAGE enhances cellular sensitivity to AL-induced suppression of MTT reduction. RAGE-transfected COS cells
(A) or PC12 cells (B,C) were exposed to the indicated concentrations of AL(25^35) alone or in the presence of sRAGE (as indicated).
In B, sRAGE was added at a 20-fold molar excess compared with AL, and in C, the AL concentration was 1 WM. *P6 0.01;
#P6 0.05. Adapted from [43].
BBADIS 61957 4-7-00 Cyaan Magenta Geel Zwart
S.D. Yan et al. / Biochimica et Biophysica Acta 1502 (2000) 145^157148
e¡ects of AL occurred at lower concentrations of AL,
whereas other mechanisms predominate at higher
levels.
An example of the potential impact of RAGE-
mediated cellular activation on the biology of AD
is illustrated by AL-RAGE-induced activation of
NF-kB, resulting in increased expression of M-CSF
[67]. The presence of M-CSF antigen in AD brain,
especially in proximity to sites of AL deposition was
evident, compared with age-matched controls (Fig.
3A,B). Furthermore, increased levels of M-CSF anti-
gen were observed in cerebrospinal £uid of patients
with AD, suggesting the relevance of M-CSF as a
barometer of cellular perturbation in AD (Fig. 3C).
However, M-CSF was also present in cerebrospinal
£uid from patients with Parkinson’s disease, indicat-
ing that, as expected, increased expression of M-CSF
was not speci¢c for AD. Production of M-CSF by
neurons bearing RAGE at sites of cellular perturba-
tion recruits microglia, as they express c-fms [71], the
M-CSF receptor (Fig. 3D). Key consequences of M-
CSF stimulation of microglia include enhanced sur-
vival in response to cellular stress, proliferation and
modulation of gene expression, such as upregulation
of MSR and apoE. The protective e¡ect of M-CSF
for the microglial response to AL was modelled by
exposing transformed murine macrophages (BV-2
cells) to AL ; preincubation of BV-2 cells with M-
CSF maintained MTT reduction (Fig. 4A) and intact
cellular morphology in the presence of AL compared
with BV-2 cells exposed to AL in the absence of M-
CSF (Fig. 4B^E). In contrast, neurons, which do not
display c-fms, did not bene¢t from the protective
e¡ects of M-CSF and must withstand the added
stress of an environment rich in activated microglia
releasing potentially toxic products.
The presence of RAGE in the vascular wall, in
both endothelial and smooth muscle cells, is also
likely to mediate interactions with the amyloid pep-
tide deposited in the vessel wall. Using an in vitro
system to analyze AL transport across the endothe-
lial monolayer, blockade of RAGE suppressed
W36% of apical to basal transit of AL [52]. These
data, along with other evidence demonstrating the
presence of RAGE in choroid plexus vasculature,
suggest that RAGE could contribute to transfer of
AL between the blood and cerebrospinal £uid com-
partments.
Fig. 3. M-CSF expression in AD brain. Immunostaining of
temporal lobe from AD (A) or age-matched control (B) brain
displaying M-CSF antigen. The inset to A shows double stain-
ing with M-CSF in red and AL in black. (C) Levels of M-CSF
in the cerebrospinal £uid of patients with AD harvested post-
mortem compared with age-matched controls and patients with
other neurologic disease (PD, Parkinson’s disease; ALS, amyo-
trophic lateral sclerosis ; MS, multiple sclerosis). #P6 0.01. (D)
Schematic depiction of AL interaction with RAGE on neurons
leading to elaboration of M-CSF which recruits microglia to
sites of cellular perturbation. Adapted from [67].
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Our results of RAGE-dependent cellular activation
raise many questions with respect to the biology of
the receptor and its possible contribution to the biol-
ogy of AD. First, it is important to understand
whether RAGE interacts with soluble AL and/or
AL ¢brils, as cellular toxicity is closely associated
with formation of L-sheet ¢brils [27,28,30,72,73].
Our pilot work shows that although RAGE binds
soluble AL, it promotes ¢brillogenesis, and interacts
with ¢brillar AL, as well as other L-sheet ¢brils, in-
cluding those formed by subunits of the prion pep-
tide, amylin, and amyloid A. Second, it is critical to
establish whether RAGE functions as a cell surface
tethering site for AL ¢brils with intrinsic bioactivity
(for example, ¢brillar AL has been shown to elabo-
rate reactive oxygen species) [29], or if it functions as
a signal transduction receptor. To address this issue,
a dominant negative form of RAGE has been pre-
pared by deleting the cytosolic tail. Although this
form of the receptor allows the receptor to e¡ectively
engage ligand (since the extracellular domain is intact
and anchored to the cell membrane), it does not
promote AL-mediated modulation of cellular proper-
ties in the range of 1039 to 1036 M. Taken together
with the data cited above, these ¢ndings suggest the
possible involvement of RAGE in pathologic
changes of AD, and support the concept that
RAGE is an important cellular cofactor capable of
propagating AL-mediated cellular stress. Rather than
being a cause of AD, as with mutant forms of LAPP
or presenilins [12^14], or conferring increased risk of
AD, as with apoE4/E4 genotype or K2-macroglobu-
lin [12,19,20,22,23], we propose that RAGE exacer-
bates cellular stress due to local changes in AL. One
likely scenario would be RAGE-mediated promotion
of ¢bril formation in proximity to the cell surface,
Fig. 4. M-CSF enhances survival of transformed murine microglial cells (BV-2) to AL. BV-2 cells were incubated in medium alone (0)
or medium containing M-CSF (50 ng/ml) and were exposed to AL(25^35) at the indicated concentration (A) or AL(1^42; 2.5 WM)
(B^E). Four hours later, reduction of MTT was assessed (A) and 24 h later. morphology was assessed by phase contrast microscopy
(B^E). In B^E, experimental conditions were: medium alone (B); medium+AL (C); medium+AL+M-CSF (D); and medium+M-CSF.
*P6 0.01. Adapted from [67].
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thereby magnifying the e¡ects of ¢brils when they
are present at low concentrations and not yet depos-
ited at appreciable levels in the extracellular space.
The key test of these hypotheses is likely to come
from experiments in transgenic mice overexpressing
mutant forms of LAPP [15,74^76]. We propose that
overexpression of neuronal and/or microglial RAGE
in an AL-rich environment will add a cellular cofac-
tor for AL present at only low levels in mouse brain,
in contrast to human AD brain. Alternatively, ex-
pression of the dominant negative form of RAGE
or a homozygous RAGE null mouse (if viable) might
be expected to have a relatively protected phenotype.
Experiments are in progress to test these concepts.
One ¢nal note concerns a report in the literature [98]
indicating that PC12 lines that do not express RAGE
display evidence of toxicity following exposure to
AL(25^35) at v 10 WM). This paper raises several
important issues. First, at higher concentrations of
synthetic AL-related peptides in vitro, there are likely
to be multiple receptor-independent/non-speci¢c
mechanisms through which AL species modulate cel-
lular properties. The ability of the peptide to gener-
ate oxygen free radicals and to directly damage cell
membranes is well-known [25,29]. In order to de-
termine whether an e¡ect of AL involves RAGE,
speci¢c strategies to block the receptor must be em-
ployed, including anti-RAGE IgG or overexpression
of tail-deleted/dominant-negative RAGE [33]. Sec-
ond, detection of a receptor such as RAGE must
utilize more than one method (such as PCR with
non-ideal primers); although RAGE is not necessa-
rily present on all lines of PC12 cells (cell lines are
well-known for their variable expression of many
polypeptides), it can be easily detected at the
mRNA or antigen level in primary cultures of rat
primary cortical neurons and certain lines of PC12
cells [59,60,99].
3. Role of amyloid beta-peptide binding alcohol
dehydrogenase in AL-induced cell stress
Recent observations from several groups have
demonstrated intracellular processing of LAPP with
generation of AL within the endoplasmic reticulum
and Golgi [77^82]. Generation of AL within cells
suggests an even more proximal mechanism than
cell surface receptors through which the amyloido-
genic peptide might exert toxic e¡ects at vulnerable
intracellular sites. This led us to consider a role for
intracellular targets of AL. Initially, using the yeast
two-hybrid system, and, subsequently, by ligand
binding assays with puri¢ed polypeptides, our group
identi¢ed ABAD, a single-chain W27-kDa polypep-
tide present in endoplasmic reticulum and mitochon-
dria, as an AL binding protein. (Note: we initially
termed this AL binding polypeptide ERAB, but have
changed the name to ABAD in view of its functional
properties [83], see below.) Half-maximal occupancy
of ABAD binding sites for AL occurred at [ABAD]
W40^70 nM. Based on FASTA and BLAST se-
quence homology database searches (Biological
Workbench, http:biology.ncsa.uiuc.edu), ABAD
was observed to be a member of the superfamily of
oxido-reductases, or short-chain alcohol dehydrogen-
ase reductases (SDR), and collectively known as L-
hydroxydehydrogenase enzymatic proteins. Common
characteristics of this superfamily are the require-
ments for a dinucleotide cofactor, either nicotin-
amide adenine dinucleotide (NAD[H] or NADP[H]),
and a Rossman-fold structural topology with an in-
variant sequence, Tyr-X-X-X-Lys (corresponding to
residues 168^172 in ABAD), all of which are re-
quired for enzymatic activity. More than 25 struc-
tures have been determined and are from the Brook-
haven Protein Database (PDB). Sequence identity
scores within the SDR superfamily are observed to
range from 12 to 35% [84]. FASTA searching on the
PDB database, according to the ABAD sequence,
revealed several known structures that had sequence
identities above 29%. What is unique about ABAD
within this family is its capacity to bind AL, and to
modulate cellular properties in an AL-rich environ-
ment. Furthermore, its expression at high levels in
a¡ected portions of AD brain, compared with age-
matched control brain (Fig. 5), places ABAD at the
site of disturbed cellular functions.
ABAD is present in endoplasmic reticulum and
mitochondria. Although there are strong similarities
to other members of the SDR family, being a revers-
ible oxidoreductase, there are also signi¢cant di¡er-
ences. First, it is a more general alcohol dehydrogen-
ase [83]. ABAD catalyzes oxidation of a variety of
simple alcohols (C2^C10) to their respective alde-
hydes in the presence of NAD, and utilizes steroid
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substrates, promoting the NAD-dependent oxidation
of 17L-estradiol (our most recent data also demon-
strates metabolism of all-trans retinol) (Fig. 6). Un-
expectedly, ABAD interacts with AL in a sequence-
speci¢c manner [85] ; it binds to AL(1^40/1^42) in
either predominately random or L-sheet conforma-
tions, but not to scrambled AL(1^40) or unrelated
peptides. Determinants of AL mediating binding to
ABAD appear to be localized in the more hydro-
philic N-terminus (residues 1^20) [86] rather than in
the C-terminal portion (for example, AL [25^35] does
not bind ABAD, nor do other peptides/polypeptides
capable of assembling into L-¢brils, amylin, serum
amyloid A or prion peptide (residues 109^141)). Fur-
thermore, LAPP does not interact with ABAD.
Cross-competition studies indicated that AL(1^20)
and AL(1^40/42) interacted with overlapping/identi-
cal sites. Complex formation between AL(1^20) and
ABAD was directly demonstrated by a⁄nity chro-
matography and isoelectric focussing. Experiments
with another steroid dehydrogenase, 3K,20L-hydrox-
ysteroid dehydrogenase, showed no binding to AL(1^
20 or 1^40).
Most importantly, in an AL-rich environment,
ABAD potentiates AL-induced cell stress and cyto-
toxicity [83,85]. Neuroblastoma or COS cells cotrans-
fected to overexpress wild-type (wt) ABAD and Lon-
don-type mutant LAPP(V717G), the latter causing
endogenous overproduction of AL(1^42) [87], dis-
played DNA fragmentation and generation of reac-
tive aldehydes, compared with mock-transfected con-
trols [83] (Fig. 7). The speci¢city of this system for
monitoring e¡ects of ABAD and LAPP/AL was dem-
onstrated by replacing wild-type (wt)-ABAD with a
mutationally inactivated form of the enzyme
(Y168G, K172G); there was no increase in reactive
aldehydes or in DNA fragmentation [83]. Taken to-
gether, these properties of ABAD suggested its at-
tractiveness as an intracellular target of AL :
b ABAD is present in the endoplasmic reticulum,
localized to a potential hot spot, along with pre-
senilins and LAPP, at a site in which LAPP pro-
cessing generates AL(1^42) [77].
b ABAD is also present in mitochondria, and is
likely to participate in fatty acid L-oxidation, a
central pathway for generating acetyl-CoA and
ATP [88,89]. Furthermore, impaired function of
mitochondria from AD brain has been previously
demonstrated [90^93].
b ABAD binds AL at nanomolar levels, indicating
Fig. 6. Enzymatic activity of ABAD for reduction of S-acetoacetyl-coenzyme A (left panel), and oxidation of octanol (middle panel)
and 17L-estradiol (right panel). Left panel : ABAD (0.33 Wg/ml) was incubated with the indicated amounts of S-acetoacetyl-CoA and
NADH (0.1 mM). Middle panel : ABAD (20 Wg/ml) was incubated with the indicated amounts of octanol and NAD (7.5 mM). Right
panel : ABAD (30 Wg/ml) was incubated with the indicated amounts of 17L-estradiol and NAD (0.4 mM). The velocity (V) of the re-
action (U/mg of protein) is plotted versus added substrate concentration. Parameters were: left panel, KmW0.068 mM; middle panel
KmW43 mM; right panel, KmW0.014 mM. Adapted from [83].
Fig. 5. Expression of ABAD in age-matched control (A) and
AD brain (B) temporal lobe using anti-ABAD IgG. The inset
in B shows double staining with ABAD in red and AL in black.
Adapted from [85].
BBADIS 61957 4-7-00 Cyaan Magenta Geel Zwart
S.D. Yan et al. / Biochimica et Biophysica Acta 1502 (2000) 145^157152
the plausibility of such an interaction early in AD.
Furthermore, occupancy of AL binding sites on
ABAD, over a range of AL concentrations,
W20^400 nM, does not alter the activity of
ABAD towards its substrates in vitro, suggesting
that AL has a more subtle e¡ect on the enzyme’s
properties [83]. For example, in certain cell types,
in an AL-rich environment, ABAD translocates
from the endoplasmic reticulum to cell membrane,
coincident with generation of reactive aldehydes.
b ABAD potentiates AL-induced cytotoxicity using
in vitro experimental systems, suggesting the pos-
sible relevance of ABAD to AL-mediated cellular
perturbation [83,85].
Our most recent pilot data provide the impetus for
further analysis of ABAD by indicating possible
mechanisms underlying ABAD^AL modulation of
cellular targets, and by demonstrating increased ex-
pression of ABAD in neurons in AD brain, and at
sites of in£ammation and ischemic brain injury. An
important clue as to how ABAD^AL complex may
modulate a range of cellular properties is the ob-
served increased generation of reactive oxygen inter-
mediates (ROIs) in cells overexpressing ABAD and
mutant LAPP(V717G). We speculate that elabora-
tion of ROIs at intracellular sites remote from pro-
tective mechanisms allows ABAD^AL-induced cellu-
lar perturbation to be severe and sustained. In
contrast, in the absence of high levels of AL,
ABAD appears to have protective properties: sta-
bly-transfected COS cells overexpressing wtABAD
have increased survival in medium with L-hydroxy-
butyrate as the principal energetic source, whereas
COS cells overexpressing mutationally inactivated
ABAD or mock-transfected controls rapidly lose
their viability under these conditions [100]. Transgen-
ic mice with targeted neuronal overexpression of
ABAD display strokes of reduced volume, compared
with non-transgenic controls. Our model for consid-
eration of the properties of ABAD has evolved as
follows:
under physiologic conditions
ABAD contributes to cellular homeostasis
in mitochondria by participating in fatty
acid L-oxidation, and as an alcohol dehy-
drogenase; in the endoplasmic reticulum,
ABAD may serve as a generalized alcohol
dehydrogenase, and may have yet-to-be
discovered properties in protein biosynthe-
sis/processing. Low levels of AL present
under homeostatic conditions do not trig-
ger pathologic responses of ABAD de-
scribed below.
under pathologic conditions in the presence of
AL(1^42)
ABAD interacts with AL within the cell,
and the resulting ABAD^AL complex in-
duces cell stress, thereby exaggerating tis-
sue injury in response to environmental
challenges, such as in£ammatory and is-
chemic stimuli.
Fig. 7. Coexpression of ABAD and mutant LAPP (LAPP(V717G)) in COS cells enhances DNA fragmentation (A) and generation of
4-hydroxynonenal (B). (A) COS cells were cotransfected with plasmids causing overexpression of the indicated protein (wild-type (wt)
ABAD or LAPP(V717G). After 48 h, samples were harvested for ELISA to detect cytoplasmic histone-associated DNA fragments. (B)
Quantitative analysis of 4-hydroxynonenal epitope expression in COS cells expressing wild-type ABAD with or without LAPP
(V717G). Experiments were performed with murine monoclonal antibody prepared to 4-hydroxynonenal lysine [96,97], and primary
data were analyzed by NIH Image. Relative £uorescence intensity is shown. *P6 0.01. Adapted from [83].
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Our results with ABAD raise many questions as to
whether it is a central cofactor in AL-mediated cell
stress. First, it will be essential to determine whether
ABAD’s e¡ects on cellular properties result from di-
rect ABAD^AL interaction within intact cells, and, if
so, which determinants in the molecule mediate such
binding. Based on the data described above, it would
seem that the AL binding site in ABAD is distinct
from the enzyme’s active site. Second, the mecha-
nisms through which ABAD, modulated by the pres-
ence of AL, disturbs cellular properties leading to
oxidant stress and apoptosis remains to be precisely
delineated. Third, the e¡ect of ABAD on cellular
function in an AL-rich environment in vivo must
be established. Our recent pilot studies in transgenic
mice overexpressing mutant forms of LAPP (to pro-
vide an AL-rich environment) indicate that ABAD is
present at very low levels, in contrast to its higher
levels in AD brain. Thus, a transgenic approach in
which ABAD is overexpressed in these models might
directly address the question of whether this enzyme
has pathogenic properties in AD.
In view of the association of AD with decreased
glucose transporter activity at the blood^brain bar-
rier and in cerebral cortex [94,95], suggesting that
maintenance of neuronal energy homeostasis might
be accomplished through upregulation of other met-
abolic pathways, such as those utilizing ketone
bodies or fatty acid L-oxidation, we would propose
that ABAD is a component of such a compensatory
pathway. However, its interaction with AL, resulting
in generation of toxic species, constitutes a protective
host response gone awry in the context of AD. Our
ABAD-dependent model of AL cytotoxicity must be
appropriately placed in the broader context of AL-
induced cellular perturbations: (1) cellular targets of
AL, such as ABAD, are not a cause of AD, but,
rather, constitute progression factors exacerbating
cytotoxicity of AL, analogous to our discussion of
possible contributions of RAGE to AD pathogene-
sis; (2) although we believe ABAD contributes to
AL-induced cellular damage, this is not an exclusive
mechanism; thus, ABAD^AL interaction occurs
against a backdrop of AL perturbation of other cel-
lular properties (for example, AL activation of tau-1
kinase/glycogen synthase kinase-3L) [90,91]; and (3)
at high levels of AL, speci¢c cellular targets may
contribute to a lesser extent to AL-induced cytotox-
icity. These caveats indicate the importance of delin-
eating the role of ABAD in AL-induced toxicity in
cell culture and using in vivo systems, the key goal of
our future work.
4. Hypothesis
We propose that RAGE and ABAD are cellular
cofactors which contribute to the progression of AL-
induced cell stress by magnifying the e¡ects of low
concentrations of AL on vulnerable cellular targets
early in the disease process. RAGE binds both solu-
ble and ¢brillar AL, and might contribute to ¢brillo-
genesis thereby localizing ¢brils in close relation to
the cell surface and, through receptor-dependent sig-
nalling mechanisms, modulating cellular properties
(Fig. 8A). ABAD’s presence within the endoplasmic
reticulum, a site for the generation of AL(1^42), pla-
Fig. 8. Schematic depiction of RAGE (A) and ABAD (B) as
cellular cofactors propagating the cellular response to AL-in-
duced cell stress.
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ces it at a critical intracellular locus where induction
of cell stress perturbs cellular energetic and biosyn-
thetic capabilities (Fig. 8B). We propose that follow-
ing AL interaction with ABAD, either directly or
indirectly, the enzyme promotes cellular mechanisms
generating reactive oxygen species and toxic alde-
hydes, such as 4-hydroxynonenal. Each of these
mechanisms highlights possible contributions of solu-
ble forms of AL which potentially mediate toxicity at
the cell surface or intracellularly (dimers, oligomers,
di¡usible non-¢brillary ligands or nascent ¢brils)
[5,101], rather than material sequestered within dense
extracellular plaques. Such material can interact with
the cell surface, be taken up by endocytotic mecha-
nisms, and have further e¡ects within the cell. The
importance of analyzing the contributions of RAGE
and ABAD to AL-induced cell stress is that inhibi-
tion of their interaction with AL might provide a
novel means for neuroprotective therapy at a time
when cellular damage is still reversible. Although
there are certainly other cellular cofactors contribu-
ting to cell stress and cytotoxicity in AD, the key
issue is to utilize available in vitro and in vivo models
to assess the possible impact of each. Such studies
are in progress with respect to RAGE and ABAD.
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